search
subscribe by email
Twitter
-
Recent Posts
current comments
topics
- #RunningAtlas (1)
- Adaptive Sports (1)
- Atlas Venture (36)
- Bioentrepreneurship (36)
- Biotech financing (101)
- Biotech investment themes (47)
- Biotech startup advice (65)
- Boards and governance (14)
- Boston Cluster (13)
- Business Development (44)
- Capital efficiency (25)
- Capital markets (48)
- Corporate Culture (52)
- Diagnostics (2)
- Drug discovery (26)
- Exits IPOs M&As (126)
- External R&D (15)
- FDA (3)
- From The Trenches (254)
- Fundraising (15)
- General Venture Capital (46)
- Governance (2)
- Leadership (34)
- Marketing (1)
- New business models (34)
- Patients (11)
- Personal (2)
- Personalized Medicine (4)
- Pharma industry (73)
- Portfolio news (64)
- Pricing and Policy (5)
- R&D Productivity (23)
- Rare Diseases (12)
- Science & Medicine (49)
- Strategy (4)
- Talent (53)
- The Human Element (9)
- Translational research (41)
- Uncategorized (24)
- VC-backed Biotech Returns (67)
monthly archive
- December 2024 (1)
- November 2024 (1)
- October 2024 (2)
- September 2024 (2)
- August 2024 (2)
- July 2024 (3)
- June 2024 (2)
- May 2024 (4)
- April 2024 (4)
- March 2024 (3)
- February 2024 (2)
- January 2024 (4)
- November 2023 (3)
- October 2023 (2)
- September 2023 (1)
- August 2023 (1)
- July 2023 (2)
- June 2023 (1)
- May 2023 (1)
- April 2023 (2)
- March 2023 (3)
- February 2023 (3)
- January 2023 (1)
- December 2022 (2)
- November 2022 (3)
- October 2022 (3)
- September 2022 (1)
- August 2022 (1)
- July 2022 (2)
- June 2022 (4)
- May 2022 (2)
- April 2022 (4)
- March 2022 (7)
- February 2022 (2)
- January 2022 (2)
- November 2021 (5)
- October 2021 (1)
- September 2021 (1)
- August 2021 (2)
- July 2021 (5)
- June 2021 (3)
- May 2021 (3)
- April 2021 (6)
- March 2021 (3)
- January 2021 (2)
- December 2020 (3)
- November 2020 (1)
- October 2020 (6)
- September 2020 (2)
- August 2020 (2)
- July 2020 (3)
- June 2020 (3)
- May 2020 (3)
- April 2020 (6)
- March 2020 (6)
- February 2020 (1)
- January 2020 (1)
- December 2019 (3)
- November 2019 (2)
- October 2019 (2)
- September 2019 (2)
- August 2019 (2)
- July 2019 (1)
- May 2019 (7)
- April 2019 (6)
- March 2019 (1)
- February 2019 (6)
- January 2019 (5)
- December 2018 (1)
- November 2018 (2)
- October 2018 (8)
- September 2018 (4)
- August 2018 (1)
- July 2018 (1)
- June 2018 (4)
- May 2018 (3)
- April 2018 (4)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (3)
- November 2017 (4)
- October 2017 (6)
- September 2017 (4)
- August 2017 (2)
- July 2017 (1)
- June 2017 (5)
- May 2017 (4)
- April 2017 (1)
- March 2017 (5)
- February 2017 (2)
- January 2017 (7)
- December 2016 (3)
- November 2016 (4)
- October 2016 (3)
- September 2016 (6)
- August 2016 (5)
- July 2016 (3)
- June 2016 (6)
- May 2016 (5)
- April 2016 (4)
- March 2016 (7)
- February 2016 (5)
- January 2016 (6)
- December 2015 (6)
- November 2015 (3)
- October 2015 (4)
- September 2015 (5)
- August 2015 (3)
- July 2015 (3)
- June 2015 (4)
- May 2015 (6)
- April 2015 (6)
- March 2015 (7)
- February 2015 (7)
- January 2015 (5)
- December 2014 (4)
- November 2014 (3)
- October 2014 (7)
- September 2014 (5)
- August 2014 (5)
- July 2014 (4)
- June 2014 (6)
- May 2014 (5)
- April 2014 (5)
- March 2014 (6)
- February 2014 (4)
- January 2014 (5)
- December 2013 (3)
- November 2013 (2)
- October 2013 (4)
- September 2013 (3)
- August 2013 (1)
- July 2013 (2)
- June 2013 (2)
- May 2013 (4)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Author Archives: Deanna Petersen
Gene Therapy Is Here To Stay: Should Bigger Companies Build, Buy, Or Partner?
October 13, 2022
By Deanna Petersen, CBO of AVROBio, as part of the From the Trenches feature of LifeSciVC Gene therapy’s tremendous potential to transform the treatment of both rare and common diseases has been understood for decades. But few may appreciate how
International Partnerships in Biotech: How Small Details Can Have a Big Impact
June 16, 2022
By Deanna Petersen, CBO of AVROBIO, and Ted Tanaka, consultant with Tanaka International LLC, as part of the From The Trenches feature of LifeSciVC Imagine yourself setting out to do business in Japan. You step off the plane, check into
Going Out On A Limb: Lessons I’ve Learned Chasing My Dreams
March 2, 2022
By Deanna M. Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC One of the most common questions I get asked is how I got into the business side of the biotech industry, and in
Understanding The Business Model Of Gene Therapy Companies – Peeling The Onion Back To Understand Why Time Matters
November 4, 2021
By Deanna Petersen and Holly May, Chief Business Officer and Chief Commercial Officer, respectively, of AVROBIO, as part of the From The Trenches feature of LifeSciVC Moving from traditional drug development and commercialization to gene therapy development and commercialization can
Mind Your Manners: Best Practices and Basic Etiquette in Business Development
August 16, 2021
By Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC It’s tempting to think that the first skill you need to learn in business development is negotiating. That’s important, of course, but it should
You Want To Be A CBO? Four Tips To Set You On Your Way
May 3, 2021
By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC Most of the titles in a biotech C-suite are generally self-explanatory. The Chief Technical and Manufacturing Officer runs operations in CMC and
Negotiating 101: Advice From The Trenches
October 27, 2020
Part 2: Gaining leverage – and using it wisely By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC. In a recent blog post, I walked through my tips for reading your adversaries’
Negotiating 101: Advice From The Trenches
October 22, 2020
Part 1: Maintaining your cool – while making your adversary sweat By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC It’s back-to-school season, and that puts me in the frame of
Nurturing A Culture Of “Smart Speed” To Bring Gene Therapy To The World
June 23, 2020
By Deanna Petersen, chief business officer at AVROBIO, and Georgette Verdin, chief human resources officer at AVROBIO, as part of the From The Trenches feature of LifeSciVC. As we approach our 5th anniversary and surpass our 125th hire, we have
Recipe For Managing Data Disclosure Successfully With Academic Partners: A Public Gene Therapy Company Perspective
March 24, 2020
This blog post was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC. When AVROBIO went public in June 2018, I found myself on the steep end of an unexpected but interesting
Leave No Stone Unturned: A Pipeline Story
October 10, 2019
This blog was written by Deanna Petersen, CBO of AVROBIO (@dmp9818), as part of the From The Trenches feature of LifeSciVC. Building a leading gene therapy pipeline in under two years (and a lot of air miles): how to persevere
Why Reputation Is More Important Than Ever For Biotech Companies … And What You Can Do About It
April 24, 2019
This blog was co-written by Deanna Petersen, Chief Business Officer of AVROBIO, and Paul Newman, head of Corporate Communications, as part of the From The Trenches feature of LifeSciVC. “It takes twenty years to build a reputation, and five minutes
Leadership At All Levels In Biotech
January 23, 2019
This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC Biotech is an industry that calls for leaders. It requires people who are willing to take risks, conquer new science,
Bring Your A-Game for BD
October 9, 2018
This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC. As with most professions – especially those that involve longer-term outcomes – the way people get good at BD is
We Saw It Coming In Pharma: Now Gene Therapy Is Biotech 2.0 For Rare Diseases
February 1, 2018
This blog was written by Deanna Petersen, Chief Business Officer of AvroBio, as part of the From The Trenches feature of LifeSciVC. It seems so clear now: gene therapy is on a roll. As 2017 came to a close, the